Biofrontera ( (BFRI) ) has shared an announcement.
Biofrontera Inc. announced promising results from its Phase 3 study on Ameluz®-PDT for treating superficial basal cell carcinoma (sBCC). The study, conducted in the U.S., showed highly significant outcomes with 65.5% of patients achieving complete clinical and histological clearance compared to just 4.8% with placebo. With over 3 million sBCC cases annually in the U.S., these findings could lead to a new non-invasive treatment option with reduced patient burden and better cosmetic results. The company plans to submit its findings to the FDA by mid-2025.
For an in-depth examination of BFRI stock, go to TipRanks’ Stock Analysis page.
